LAMEA Guillain-Barre Syndrome Market

LAMEA Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Report Id: KBV-21416 Publication Date: March-2024 Number of Pages: 117
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The Latin America, Middle East and Africa Guillain-Barre Syndrome Market would witness market growth of 6.2% CAGR during the forecast period (2023-2030).

The Brazil market dominated the LAMEA Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $15,320.9 Thousands by 2030. The Argentina market is registering a CAGR of 7.1% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 5.9% during (2023 - 2030).

LAMEA Guillain-Barre Syndrome Market

Cerebrospinal fluid (CSF) analysis lumbar puncture is performed to obtain CSF samples for analysis, including cell counts, protein levels, and the presence of inflammatory markers such as elevated protein levels without an increase in white blood cells, indicative of albumin cytologic dissociation, a hallmark of GBS.

Additionally, magnetic resonance imaging (MRI) of the spine and nerve roots may reveal characteristic findings such as nerve root enhancement, nerve enlargement, or spinal cord abnormalities, supporting the diagnosis of GBS and ruling out other neurological conditions.

The World Health Organization (WHO) reports that 130 suspected cases of GBS were reported in Peru between June 10, 2023, and July 15, 2023. 44 of these cases have been verified. The number of instances observed has increased more than anticipated. Additionally, 231 probable GBS cases were reported in Peru between epidemiological weeks 1 and 28 (until July 15, 2023). Thus, the rising aging population and increasing healthcare expenditure in the LAMEA region propel the market’s growth.

Free Valuable Insights: The Worldwide Guillain-Barre Syndrome Market is Projected to reach USD 852.2 Million by 2030, at a CAGR of 4.6%

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • F.Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • PTC, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company

LAMEA Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others

By Route Of Administration

  • Parenteral
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo